News Summary

The process of drug discovery remains a slow and challenging journey, even with advancements in artificial intelligence. Peter Ray, a medicinal chemist at Recursion, has dedicated his life to developing cancer drugs, driven by a promise he made to his mother after witnessing her battle with the disease. Despite the potential of AI to accelerate drug development, the path from identifying a target protein to creating a successful drug involves numerous trials and errors. Chemists and biologists must meticulously design and test molecules, yet more than 90% of potential drugs fail during trials. Keith Mikule of Insilico Medicine shares the rarity of success in this field, with only a few reaching the market, such as niraparib for ovarian cancer. This highlights the ongoing challenges and the incremental progress in using AI for drug discovery.